Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

A unified personal protective equipment ensemble for clinical response to possible high consequence infectious diseases: A consensus document on behalf of the HCID programme.

Poller B, Tunbridge A, Hall S, Beadsworth M, Jacobs M, Peters E, Schmid ML, Sykes A, Poran V, Gent N, Evans C, Crook B; High Consequence Infectious Diseases Project Working Group.

J Infect. 2018 Aug 31. pii: S0163-4453(18)30261-5. doi: 10.1016/j.jinf.2018.08.016. [Epub ahead of print]

2.

'VIOLET': a fluorescence-based simulation exercise for training healthcare workers in the use of personal protective equipment.

Poller B, Hall S, Bailey C, Gregory S, Clark R, Roberts P, Tunbridge A, Poran V, Crook B, Evans C.

J Hosp Infect. 2018 Jun;99(2):229-235. doi: 10.1016/j.jhin.2018.01.021. Epub 2018 Feb 5.

3.

Use of ultraviolet-fluorescence-based simulation in evaluation of personal protective equipment worn for first assessment and care of a patient with suspected high-consequence infectious disease.

Hall S, Poller B, Bailey C, Gregory S, Clark R, Roberts P, Tunbridge A, Poran V, Evans C, Crook B.

J Hosp Infect. 2018 Jun;99(2):218-228. doi: 10.1016/j.jhin.2018.01.002. Epub 2018 Jan 8.

4.

Probing Pharmaceutical Mixtures during Milling: The Potency of Low-Frequency Raman Spectroscopy in Identifying Disorder.

Walker G, Römann P, Poller B, Löbmann K, Grohganz H, Rooney JS, Huff GS, Smith GPS, Rades T, Gordon KC, Strachan CJ, Fraser-Miller SJ.

Mol Pharm. 2017 Dec 4;14(12):4675-4684. doi: 10.1021/acs.molpharmaceut.7b00803. Epub 2017 Nov 16.

PMID:
29091447
5.

Current In Vitro Methods to Determine Hepatic Kpuu: A Comparison of Their Usefulness and Limitations.

Riede J, Camenisch G, Huwyler J, Poller B.

J Pharm Sci. 2017 Sep;106(9):2805-2814. doi: 10.1016/j.xphs.2017.03.025. Epub 2017 Apr 4.

PMID:
28385545
6.

Musculoskeletal manifestations of Ebola virus.

Amissah-Arthur MB, Poller B, Tunbridge A, Adebajo A.

Rheumatology (Oxford). 2018 Jan 1;57(1):28-31. doi: 10.1093/rheumatology/kex082. Review.

PMID:
28379487
7.

Assessing the Risk of Drug-Induced Cholestasis Using Unbound Intrahepatic Concentrations.

Riede J, Poller B, Huwyler J, Camenisch G.

Drug Metab Dispos. 2017 May;45(5):523-531. doi: 10.1124/dmd.116.074179. Epub 2017 Mar 2.

8.

A minitablet formulation made from electrospun nanofibers.

Poller B, Strachan C, Broadbent R, Walker GF.

Eur J Pharm Biopharm. 2017 May;114:213-220. doi: 10.1016/j.ejpb.2017.01.022. Epub 2017 Feb 4.

PMID:
28167295
9.

New IVIVE method for the prediction of total human clearance and relative elimination pathway contributions from in vitro hepatocyte and microsome data.

Riede J, Poller B, Umehara K, Huwyler J, Camenisch G.

Eur J Pharm Sci. 2016 Apr 30;86:96-102. doi: 10.1016/j.ejps.2016.02.022. Epub 2016 Mar 3.

PMID:
26948853
10.

Application of the extended clearance concept classification system (ECCCS) to predict the victim drug-drug interaction potential of statins.

Kunze A, Poller B, Huwyler J, Camenisch G.

Drug Metab Pers Ther. 2015 Sep;30(3):175-88. doi: 10.1515/dmdi-2015-0003.

PMID:
25996489
11.

Prediction of organic anion-transporting polypeptide 1B1- and 1B3-mediated hepatic uptake of statins based on transporter protein expression and activity data.

Kunze A, Huwyler J, Camenisch G, Poller B.

Drug Metab Dispos. 2014 Sep;42(9):1514-21. doi: 10.1124/dmd.114.058412. Epub 2014 Jul 2.

12.

In vitro-in vivo extrapolation method to predict human renal clearance of drugs.

Kunze A, Huwyler J, Poller B, Gutmann H, Camenisch G.

J Pharm Sci. 2014 Mar;103(3):994-1001. doi: 10.1002/jps.23851. Epub 2014 Jan 13.

PMID:
24549735
13.

In vitro P-glycoprotein efflux inhibition by atypical antipsychotics is in vivo nicely reflected by pharmacodynamic but less by pharmacokinetic changes.

Schmitt U, Kirschbaum KM, Poller B, Kusch-Poddar M, Drewe J, Hiemke C, Gutmann H.

Pharmacol Biochem Behav. 2012 Aug;102(2):312-20. doi: 10.1016/j.pbb.2012.04.002. Epub 2012 Apr 15.

PMID:
22525746
14.

P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) restrict brain accumulation of the active sunitinib metabolite N-desethyl sunitinib.

Tang SC, Lankheet NA, Poller B, Wagenaar E, Beijnen JH, Schinkel AH.

J Pharmacol Exp Ther. 2012 Apr;341(1):164-73. doi: 10.1124/jpet.111.186908. Epub 2012 Jan 11.

15.

Brain accumulation of sunitinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration.

Tang SC, Lagas JS, Lankheet NA, Poller B, Hillebrand MJ, Rosing H, Beijnen JH, Schinkel AH.

Int J Cancer. 2012 Jan 1;130(1):223-33. doi: 10.1002/ijc.26000. Epub 2011 Apr 7.

16.

Double-transduced MDCKII cells to study human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) interplay in drug transport across the blood-brain barrier.

Poller B, Wagenaar E, Tang SC, Schinkel AH.

Mol Pharm. 2011 Apr 4;8(2):571-82. doi: 10.1021/mp1003898. Epub 2011 Mar 4.

PMID:
21309545
17.

Differential impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on axitinib brain accumulation and oral plasma pharmacokinetics.

Poller B, Iusuf D, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH.

Drug Metab Dispos. 2011 May;39(5):729-35. doi: 10.1124/dmd.110.037317. Epub 2011 Jan 31.

18.

Bioactive xanthones from the roots of Hypericum perforatum (common St John's wort).

Crockett SL, Poller B, Tabanca N, Pferschy-Wenzig EM, Kunert O, Wedge DE, Bucar F.

J Sci Food Agric. 2011 Feb;91(3):428-34. doi: 10.1002/jsfa.4202. Epub 2010 Oct 27.

19.

Oral administration of glucagon-like peptide 1 or peptide YY 3-36 affects food intake in healthy male subjects.

Steinert RE, Poller B, Castelli MC, Drewe J, Beglinger C.

Am J Clin Nutr. 2010 Oct;92(4):810-7. doi: 10.3945/ajcn.2010.29663. Epub 2010 Aug 18.

PMID:
20720259
20.

Cytokine signaling in the human brain capillary endothelial cell line hCMEC/D3.

Fasler-Kan E, Suenderhauf C, Barteneva N, Poller B, Gygax D, Huwyler J.

Brain Res. 2010 Oct 1;1354:15-22. doi: 10.1016/j.brainres.2010.07.077. Epub 2010 Aug 6.

PMID:
20692239
21.

Orally administered glucagon-like peptide-1 affects glucose homeostasis following an oral glucose tolerance test in healthy male subjects.

Steinert RE, Poller B, Castelli MC, Friedman K, Huber AR, Drewe J, Beglinger C.

Clin Pharmacol Ther. 2009 Dec;86(6):644-50. doi: 10.1038/clpt.2009.159. Epub 2009 Sep 2.

PMID:
19727071
22.

Regulation of BCRP (ABCG2) and P-glycoprotein (ABCB1) by cytokines in a model of the human blood-brain barrier.

Poller B, Drewe J, Krähenbühl S, Huwyler J, Gutmann H.

Cell Mol Neurobiol. 2010 Jan;30(1):63-70. doi: 10.1007/s10571-009-9431-1. Epub 2009 Jul 23.

PMID:
19629677
23.

Pharmacokinetics and pharmacodynamic effects of oral GLP-1 and PYY3-36: a proof-of-concept study in healthy subjects.

Beglinger C, Poller B, Arbit E, Ganzoni C, Gass S, Gomez-Orellana I, Drewe J.

Clin Pharmacol Ther. 2008 Oct;84(4):468-74.

PMID:
19238651
24.

The human brain endothelial cell line hCMEC/D3 as a human blood-brain barrier model for drug transport studies.

Poller B, Gutmann H, Krähenbühl S, Weksler B, Romero I, Couraud PO, Tuffin G, Drewe J, Huwyler J.

J Neurochem. 2008 Dec;107(5):1358-68.

PMID:
19013850
25.

Hypericum perforatum: which constituents may induce intestinal MDR1 and CYP3A4 mRNA expression?

Gutmann H, Poller B, Büter KB, Pfrunder A, Schaffner W, Drewe J.

Planta Med. 2006 Jun;72(8):685-90. Epub 2006 Jun 1.

PMID:
16755466
26.

Forensic odontology: a responsibility of the general practitioner.

Poller B.

J Acad Gen Dent. 1975 Sep-Oct;23(5):33-6. No abstract available.

PMID:
1065656

Supplemental Content

Loading ...
Support Center